Arotinolol
产品说明书
 |
同义名 : | - |
| CAS号 : | 68377-92-4 | |
| 货号 : | A127295 | |
| 分子式 : | C15H21N3O2S3 | |
| 纯度 : | 95% | |
| 分子量 : | 371.54 | |
| MDL号 : | MFCD00865895 | |
| 存储条件： |
Pure form Keep in dark place, sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 120 mg/mL(322.98 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol(30 mg/kg/d) relaxed vascular rings and the relaxations were attenuated by Nω-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) and the absence of endothelium[3]. On the beta3-receptor, arotinolol was a very weak (EC50 approximately 20 mM) and only partial (approximately 50%) agonist, but arotinolol also demonstrated the properties of being a beta3-receptor antagonist with a pK(B) of 5.7[4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01351636 | Chronic Kidney Disease | Phase 4 | Unknown | September 2018 | China, Shanghai ... 展开 >> Nan Chen Shanghai, Shanghai, China, 200025 收起 << |
| NCT02612298 | Essential Hypertension | Phase 4 | Unknown | December 2018 | China ... 展开 >> China PLA General Hospital Recruiting Beijing, China, 100039 Contact: Yundai Chen, MD Contact: Yundai Chen, MD +86 010 55499209 cyundai@medmail.com.cn 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.69mL 0.54mL 0.27mL |
13.46mL 2.69mL 1.35mL |
26.92mL 5.38mL 2.69mL |
| 参考文献 |
|---|